Allostery Investments’s Arcutis Biotherapeutics ARQT Stock Holding History

Allostery Investments’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,500	Closed	-$117K	–	22
2025 Q1	$117K	Buy	+7,500	New	+$106K	0.17%	39

Other funds holding ARQT

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Allostery Investments's ARQT Position: Q2 2025 in Review

Allostery Investments sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 7,500 shares — an estimated $117K sold.

Allostery Investments first reported a position in ARQT in Q1 2025 and held it in 1 quarter. The position peaked at $117K in Q1 2025. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

Allostery Investments reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
Allostery Investments sold 7,500 Arcutis Biotherapeutics shares in Q2 2025, an estimated $117K.
Allostery Investments first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 1 quarter.
Allostery Investments's Arcutis Biotherapeutics position peaked at $117K in Q1 2025.
230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on Allostery Investments's 13F filing for Q2 2025, filed 14 Aug 2025.